Glucagon Like Peptide 1 Based Therapies: A New Horizon in Obesity Management Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Incretins in Cardiometabolic Medicine: Leveraging GLP 1, GIP, and Glucagon Receptor Agonism for Cardiovascular Risk Reduction Medicating Appetite: What Ozempic, Wegovy, and Other GLP 1 Drugs Really Mean Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit